Corvus Pharmaceuticals CRVS Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's unrealized gains (losses) on available-for-sale securities?
- Corvus Pharmaceuticals (CRVS) reported unrealized gains (losses) on available-for-sale securities of -$334K in Q1 2026.
- How has Corvus Pharmaceuticals's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Corvus Pharmaceuticals's unrealized gains (losses) on available-for-sale securities decreased by 1352.2% year-over-year, from -$23K to -$334K.
- What is the long-term trend for Corvus Pharmaceuticals's unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2021 to 2025), Corvus Pharmaceuticals's unrealized gains (losses) on available-for-sale securities has grown at a 55.8% compound annual growth rate (CAGR), from -$7K to -$17K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This reflects the unrealized gains or losses on investment securities classified as available-for-sale that are not yet recognized in the income statement. It captures the impact of market price fluctuations on the company's investment portfolio held outside of core operations. This metric provides insight into the volatility and potential liquidity value of the company's treasury assets.